The application is based on clinical findings by Professor van der Lely, Head of Endocrinology in the Department of Internal Medicine. Preliminary clinical data suggest the combination might increase compliance and could greatly reduce the costs of treatment.
In addition to the €1.25 million upfront, Paris-based Ipsen will pay a further Euros 8.75 million in additional milestone payments, upon patent issue and market approvals of the product.
“This partnership allows Ipsen to further strengthen its position in endocrinology, and illustrates our commitment to offer state of the art treatment to acromegalic patients and to provide endocrinologists with optimal therapeutic choices,” said Jacques-Pierre Moreau, Chief Scientific Officer of Ipsen.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
